Skip to main
CING

Cingulate (CING) Stock Forecast & Price Target

Cingulate (CING) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cingulate is a clinical-stage biopharmaceutical company with a promising drug delivery platform technology for once-daily tablets and two first-line stimulant medications for the treatment of ADHD. The company has a positive outlook for potential FDA approval for CTx-1301 in mid-2026, with a large market potential for ADHD and a projected $18 billion in U.S. medication sales. Cingulate's commercial readiness initiatives and strategic partnerships position them for a rapid launch and potential growth, with potential risks including product efficacy and regulatory approvals.

Bears say

Cingulate is facing multiple risks such as balance sheet and liquidity concerns, potential failure of their product candidates in clinical trials, regulatory hurdles, and competition. While the usage of their PTR drug delivery platform for their ADHD medications may differentiate them, it remains to be seen if they will be able to successfully commercialize these products and obtain suitable reimbursement. Overall, there are many uncertainties surrounding the company that may hinder its potential for share price growth.

Cingulate (CING) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cingulate and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cingulate (CING) Forecast

Analysts have given Cingulate (CING) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Cingulate (CING) has a Strong Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cingulate (CING)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.